{"analyses":[{"ciLowerLimit":"0.15","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"10.38","estimateComment":"Comparison: \"Tertile 1 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.8257","paramType":"Odds Ratio (OR)","paramValue":"1.27","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.13","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"9.02","estimateComment":"Comparison: \"Tertile 1 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9467","paramType":"Odds Ratio (OR)","paramValue":"1.08","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.00","estimateComment":"Comparison: \"Tertile 2 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9859","paramType":"Odds Ratio (OR)","paramValue":"0.00","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.00","estimateComment":"Comparison: \"Tertile 2 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9857","paramType":"Odds Ratio (OR)","paramValue":"0.00","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.00","estimateComment":"Comparison: \"Tertile 3 (with 2 year lag)\" and \"Never (with 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9860","paramType":"Odds Ratio (OR)","paramValue":"0.00","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.00","estimateComment":"Comparison: \"Tertile 3 (with 2 year lag)\" and \"Never (with 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9858","paramType":"Odds Ratio (OR)","paramValue":"0.00","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.00","estimateComment":"Comparison: \"Tertile 3 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9798","paramType":"Odds Ratio (OR)","paramValue":"0.00","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.00","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.00","estimateComment":"Comparison: \"Tertile 3 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9796","paramType":"Odds Ratio (OR)","paramValue":"0.00","statisticalMethod":"Conditional Logistic Regression"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"2925"}]}],"title":"Never (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"title":"Tertile 1 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Tertile 2 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"title":"Tertile 3 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"2916"}]}],"title":"Never (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"7"}]}],"title":"Tertile 1 (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"title":"Tertile 2 (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"}]}],"title":"Tertile 3 (without 2 year lag)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"2935"}],"units":"Participants"}],"description":"Incident bone/joint cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (1-2 prescriptions \\[prescrip.\\]), T 2 (3-7 prescrip.), T 3 (8-298 prescrip.). Tertiles without 2 yr lag: T 1 (1-2 prescrip.), T 2 (3-7 prescrip.), and T 3 (8-388 prescrip.). Inestimable OR and 95% CI when no gaba.-exposed cases or controls at the exposure level.","groups":[{"description":"Patients with incident bone/joint cancer defined from READ/OXMIS codes in the years 1995-2008","id":"OG000","title":"Incident Bone/Joint Cancer Patients"},{"description":"Cancer-free control patients risk set matched with incident bone/joint cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site","id":"OG001","title":"Matched Controls for Incident Bone/Joint Cancer Patients"}],"paramType":"NUMBER","populationDescription":"Cases \\& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.","reportingStatus":"POSTED","timeFrame":"The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.","title":"Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Number of Gabapentin Prescriptions","type":"PRIMARY","unitOfMeasure":"participants"}